iBio Doses First Patient in Phase 1 Trial for Obesity Drug IBIO-600 — iBio, Inc.

Event summary

iBio dosed the first participant in its Phase 1 trial for IBIO-600, a long-acting anti-myostatin monoclonal antibody targeting obesity.
The trial is a randomized, double-blind, placebo-controlled study enrolling 32 adults with overweight and obesity.
IBIO-600 aims to preserve muscle and improve body composition during weight reduction, with a potential extended half-life of 40-52 days in humans.
Study completion is expected in the second half of 2027, with data informing future development and potential combination with GLP-1 therapies.
iBio anticipates advancing its Activin E program IBIO-610 into the clinic in the first half of 2027.

The big picture

iBio's transition to a clinical-stage company marks a strategic shift in its ability to validate its AI-driven drug discovery platform. The obesity market is increasingly competitive, with GLP-1 therapies dominating, but iBio's focus on muscle preservation could carve out a niche. Success in this trial would position iBio as a key player in addressing unmet needs in cardiometabolic and obesity care.

What we're watching

Clinical Efficacy: How IBIO-600's muscle preservation and body composition effects will translate from non-human primates to humans.
Development Speed: The pace at which iBio can advance its pipeline, with IBIO-610 expected to enter clinical trials in early 2027.
Combination Therapy: Whether IBIO-600 can be effectively combined with existing GLP-1-based obesity treatments.